Clinical Trials Logo

Lymphoma, Follicular clinical trials

View clinical trials related to Lymphoma, Follicular.

Filter by:

NCT ID: NCT00096005 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Start date: November 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of giving tanespimycin together with bortezomib in treating patients with advanced solid tumors or lymphomas. (Accrual for lymphoma patients closed as of 11/27/09) Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of tanespimycin by making cancer cells more sensitive to the drug. Combining tanespimycin with bortezomib may kill more cancer cells.

NCT ID: NCT00092274 Withdrawn - Clinical trials for Lymphoma, Follicular

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Start date: September 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).

NCT ID: NCT00091676 Active, not recruiting - Clinical trials for Non-Hodgkins Lymphoma

Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma

BiovaxID
Start date: January 2000
Phase: Phase 3
Study type: Interventional

The primary objective of this Phase 3 study is to definitively confirm the safety and efficacy of BiovaxId, an autologous tumor derived immunoglobulin idiotype vaccine, as measured by a significant prolongation of the period of disease free survival when administered to patients with indolent follicular Non-Hodgkin's Lymphoma (NHL) during their first complete remission.

NCT ID: NCT00089271 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Start date: July 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of 17-DMAG in treating patients with metastatic or unresectable solid tumors or lymphomas. Drugs used in chemotherapy, such as 17-DMAG, work in different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00089076 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Start date: June 2004
Phase: Phase 1/Phase 2
Study type: Interventional

Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop cancer cells from growing. This phase I/II trial is studying the side effects and best dose of MDX-010 and to see how well it works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma.

NCT ID: NCT00089011 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Start date: April 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by donor peripheral blood stem cell transplant for hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate, and TBI before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening.

NCT ID: NCT00086944 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Start date: May 2004
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of oblimersen when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs

NCT ID: NCT00085696 Completed - Follicular Lymphoma Clinical Trials

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.

NCT ID: NCT00082888 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Start date: March 24, 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tipifarnib may be an effective treatment for non-Hodgkin's lymphoma.

NCT ID: NCT00082784 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Start date: March 2004
Phase: Phase 1
Study type: Interventional

Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may increase the effectiveness of flavopiridol by making cancer cells more sensitive to the drug. Giving bortezomib together with flavopiridol may kill more cancer cells. This phase I trial is studying the side effects and best dose of bortezomib and flavopiridol in treating patients with recurrent or refractory indolent B-cell neoplasms.